ClinicalTrials.gg
RecruitingNCT07937839Updated Nov 16, 2026

Immune Response Profiling in Sepsis

An observational study in Sepsis, Septic Shock and Infections, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National University Hospital, Singapore · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
304
Ages
21 Years to 99 Years
Sex
All
01

Study summary

The goal of this prospective observational study is to investigate if a point-of-care testing device using microfluidics can evaluate the biophysical characteristics of white blood cells for the rapid diagnosis and prognosis of acute infection or sepsis.

Our main aim is to develop a rapid biophysical sparing assay protocol for the diagnosis and/or prognosis of acute infection and sepsis in the ED among patients with non-specific symptoms, by differentiating infection vs. non-infection in febrile cases, viral vs. bacterial cause of infection (if infection present) and low vs. high risk of sepsis with organ dysfunction.

Read the detailed description

Our primary aims are:

  1. To validate leukocyte biophysical assay for quantifying patient immune status and activity using biomarkers of white cell count, size, distribution and deformability with a point-of-care microfluidic testing device
  2. To develop a rapid biophysical sparing assay protocol for the diagnosis and/or prognosis of acute infection and sepsis in the ED among patients with non-specific symptoms
  3. To differentiate infection vs. non-infection in febrile cases, viral vs. bacterial cause of infection (if infection present) and low vs. high risk of sepsis with organ dysfunction

A total of 3 ml (slightly more than half teaspoon) of blood sample via intravenous cannulation in addition to clinically indicated full blood count will be collected from study participants and placed into EDTA vacutainer tubes. Automated aspiration of up to 100 µl of blood from the EDTA tube will be performed by the prototype and loaded onto the PDMS microfluidic device for the biophysical assay. The white blood cell biophysical properties (count, size, distribution and deformability) will be analyzed at various flow rates through the microfluidic system. Biophysical indices and characteristics will be recorded. Results will be blinded to attending clinicians.

Clinical charts will be reviewed and clinical progression of the patients charted and grouped into infective vs. no infection in febrile cases; viral vs. bacterial cause of infection (if infection present) and low vs. high risk of sepsis with organ dysfunction. The electronic medical records of subjects will be reviewed for inpatient admissions and up to 30 days from day of discharge from ED or hospital to follow up on outcomes.

02

Conditions studied

  • Sepsis
  • Septic Shock
  • Infections

Browse trials for

Keywords

  • Sepsis
  • Septic shock
  • White blood cells
  • Infection
  • Microfluidics
03

In context

Shock, Septic Reclassified

1,079 studies on the registry are indexed under Shock, Septic; 232 are open to participants now.

This study's planned enrollment of 304 is above the median of 108 across 406 observational studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

National University Hospital, Singapore is the lead sponsor of 455 studies on the registry; 100 are open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult emergency department patients, aged 21 years old and above, in whom attending clinician suspects infection (including patients with unexplained fever or vague symptoms) OR those who have a clear and objective source of systemic infection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/= 21 years old
  • Attending clinician suspects infection (including patients with unexplained fever or vague symptoms) OR
  • Patients who have a clear and objective source of systemic infection [such as pneumonia (infiltrates/consolidation on chest radiography), urinary tract infection (positive urinary leukocytes/nitrites), necrotising fasciitis (subcutaneous gas on plain radiograph or MRI-proven subcutaneous gas), hepatobiliary infection (chills and rigors, jaundice)]

Exclusion criteria

Exclusion Criteria:

  • Age \< 21 years old
  • Pregnant patients
  • Unable to obtain
  • Unconscious patients or patients with no mental capacity to provide informed consent
  • Patients with "do-not-resuscitate" order
  • Patients with medical conditions that may result in macrocytosis (that could interfere with evaluation of WBC size and deformability): vitamin B12 deficiency, primary bone marrow disorder, previous gastrectomy, pernicious anemia, alcoholism, , familial macrocytosis, hypothyroidism, oncological patients (chemo agents can result in macrocytosis)
  • Patients on medications that may result in macrocytosis: chemo agents, zidovudine, trimethoprim, phenytoin, oral pills
  • Severe neutropenia with white cell count of 0
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
304 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective observational

    A total of 3 ml (slightly more than half teaspoon) of blood sample via intravenous cannulation in addition to clinically indicated full blood count will be collected from study participants and placed into EDTA vacutainer tubes. Automated aspiration of up to 100 µl of blood from the EDTA tube will be performed by the prototype and loaded onto the PDMS microfluidic device for the biophysical assay.

    Diagnostic Test: Microfluidic device for assessment of biophysical properties of white blood cells

Interventions

  • Diagnostic testMicrofluidic device for assessment of biophysical properties of white blood cells

    Point-of-care label-free immune profiling assay from 20 µL of unprocessed blood using unconventional L and Inverse-L shaped pillars of deterministic lateral displacement microfluidic technology to characterize immune cell size, deformability, distribution, and cell counts.

06

What researchers measure

Primary outcomes

  1. Infective vs. no infection in febrile cases

    Sensitivity, specificity and accuracy of our diagnostic platform

    Time frame: Up to 30 days

  2. Viral vs. bacterial cause of infection (if infection present)

    Sensitivity, specificity and accuracy of our diagnostic platform

    Time frame: Up to 30 days

  3. Low vs. high risk of sepsis with organ dysfunction

    Sensitivity, specificity and accuracy of our diagnostic platform

    Time frame: Up to 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.

Of 188 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 10 months is below that.

Counting every sponsor, half of 201 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Jun 15, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07937839
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jun 15, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Win Sen Kuan, MBBS, MRCS(A&E)Ed, MCI, FAMS
Contact
win_sen_kuan@nuhs.edu.sg
+65 67722452

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion